, Will stock surge before Earnings results? Pluristem Therapeutics Inc. (NASDAQ:PSTI)

0
50
stock_market_daily_information
Business or finance concept : Asia Pacific stock market data and candle stick graph chart on monitor

Earnings results for Pluristem Therapeutics Inc. (NASDAQ:PSTI)

Estimate Momentum measures change in analyst sentiment over time and may be an indicator of future price movements. The Change in Consensus chart shows the current, 1 week ago, and 1 month ago consensus earnings per share (EPS*) forecasts. For the fiscal quarter endingMar 2020 , the consensus EPS* forecast has remained the same over the past week at -0.29 and decreased over the past month from -0.25 to -0.29(16.00%). none raised and none lowered their forecast. For the fiscal year ending Jun 2020 , the consensus EPS* forecast has remained the same over the past week at -1.49 and decreased over the past month from -1.36 to -1.49(9.56%). none raised and none lowered their forecast.

Analyst Opinion on Pluristem Therapeutics Inc. (NASDAQ:PSTI)

5 Wall Street analysts have issued ratings and price targets for Pluristem Therapeutics in the last 12 months. Their average twelve-month price target is $12.88, suggesting that the stock has a possible upside of 46.31%. The high price target for PSTI is $15.50 and the low price target for PSTI is $12.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of “Buy.”

Pluristem Therapeutics has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $12.88, Pluristem Therapeutics has a potential upside of 46.3% from its current price of $8.80. Pluristem Therapeutics has only been the subject of 4 research reports in the past 90 days.

Dividend Strength: Pluristem Therapeutics Inc. (NASDAQ:PSTI)

Pluristem Therapeutics does not currently pay a dividend. Pluristem Therapeutics does not have a long track record of dividend growth.

Insiders buying/selling: Pluristem Therapeutics Inc. (NASDAQ:PSTI)

In the past three months, Pluristem Therapeutics insiders have not sold or bought any company stock. Only 4.90% of the stock of Pluristem Therapeutics is held by insiders. Only 7.82% of the stock of Pluristem Therapeutics is held by institutions.

Earnings and Valuation of Pluristem Therapeutics Inc. (NASDAQ:PSTI

Earnings for Pluristem Therapeutics are expected to grow in the coming year, from ($1.49) to ($1.12) per share. The P/E ratio of Pluristem Therapeutics is -2.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Pluristem Therapeutics is -2.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Pluristem Therapeutics has a P/B Ratio of 6.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

More latest stories: here